Prof. Dr. med. Andreas Schneeweiss

Main areas of work

Inno­v­a­tive drug ther­a­pies for breast can­cer and gyne­co­log­i­cal can­cer with­in phase I‑IV stud­ies, the approved stan­dard or as off-label

• Tar­get­ed nov­el sub­stances, e.g. sig­nal trans­duc­tion inhibitors
• Immunother­a­pies
• Dose-inten­si­fied chemotherapy

Mol­e­c­u­lar pro­fil­ing for bio­mark­er eval­u­a­tion and ther­a­py stratification

• Whole genome and tran­scrip­tome sequenc­ing for 
• ear­ly high-risk breast can­cer patients (COGNITION study)
• Fort­geschrit­tene / Metas­tasierte Advanced / Metasta­t­ic Breast Can­cer Patients (CATCH Study)Brustkrebs-Patienten (CATCH-Studie)

Head of the study cen­ter at the uni­ver­si­ty women’s clinic

• Num­ber of cur­rent­ly sup­port­ed clin­i­cal stud­ies: 42 (16 recruit­ing, 18 in fol­low-up, 8 in preparation)
• Cur­rent­ly prin­ci­pal inves­ti­ga­tor or head of clin­i­cal tri­als in 11 studies
• Total num­ber of stud­ies con­duct­ed to date (phase I/II/III/IV): >120

Med­ical / pro­fes­sion­al career

Sci­en­tif­ic career

Pub­li­ca­tions 2015 — 2021 (Selec­tion)

Hlevn­jak M, Schulze M, Elgaa­fary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hut­ter B, Ishaque N, Hirsch S, Giel­d­on L, Sten­zinger A, Springfeld C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröh­ling S, Sinn HP, Jäger D, Thewes V, Zap­at­ka M, Lichter P, Schneeweiss A. CATCH: A Prospec­tive Pre­ci­sion Oncol­o­gy Tri­al in Metasta­t­ic Breast Can­cer. JCO Pre­cis Oncol. 2021. doi: 10.1200/PO.20.00248. [Epub ahead of print].

Denkert C, Sei­ther F, Schneeweiss A, Link T, Blohmer JU, Just M, Wim­berg­er P, For­berg­er A, Tesch H, Jack­isch C, Schmat­loch S, Reinisch M, Solo­may­er EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Sol­bach C, Huober J, Rhiem K, Mar­mé F, Reimer T, Schmidt M, Sinn BV, Jan­ni W, Stick­el­er E, Michel L, Stötzer O, Hah­nen E, Furlan­et­to J, Seil­er S, Neklju­do­va V, Untch M, Loibl S. Clin­i­cal and mol­e­c­u­lar char­ac­ter­is­tics of HER2-low-pos­i­tive breast can­cer: pooled analy­sis of indi­vid­ual patient data from four prospec­tive, neoad­ju­vant clin­i­cal tri­als. Lancet Oncol. 2021 .doi: 10.1016/S1470-2045(21)00301–6. [Epub ahead of print].

Schneeweiss A, Bauer­feind I, Fehm T, Jan­ni W, Thomssen C, Witzel I, Wöck­el A, Müller V. Ther­a­py Algo­rithms for the Diag­no­sis and Treat­ment of Patients with Ear­ly and Advanced Breast Can­cer. Breast Care 15:608–618, 2020.

Con­te P, Schneeweiss A, Loibl S, Mamounas EP, von Minck­witz G, Mano MS, Untch M, Huang CS, Wol­mark N, Ras­to­gi P, D’Hondt V, Redon­do A, Stam­a­tovic L, Bon­nefoi H, Cas­tro-Salguero H, Fis­ch­er HH, Wahl T, Song C, Boulet T, Trask P, Gey­er CE Jr. Patien­tre­port­ed out­comes from KATHERINE: A phase 3 study of adju­vant trastuzum­ab emtan­sine ver­sus trastuzum­ab in patients with resid­ual inva­sive dis­ease after neoad­ju­vant ther­a­py for human epi­der­mal growth fac­tor recep­tor 2‑positive breast can­cer.
Can­cer. 2020. doi: 10.1002/cncr.32873. [Epub ahead of print]
*Shared first author

Schneeweiss A, Hess D, Joerg­er M, Var­ga A, Moul­der S, Tsim­beri­dou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkin­son G, Lagkadi­nou E, Ock­er M. Phase 1 Dose Esca­la­tion Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Sol­id Can­cer-Lack of Asso­ci­a­tion between Acti­vat­ing AKT Muta­tion and AKT Inhi­bi­tion-Derived Effi­ca­cy. Can­cers 11(12). pii: E1987, 2019.

Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Küm­mel S, Untch M, Kast K, Jack­isch C, Thoma­l­la J, Ingold-Hep­p­n­er B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Neklju­do­va V, von Minck­witz G, Loibl S. Intense dose-dense epiru­bicin, pacli­tax­el, cyclophos­phamide ver­sus week­ly pacli­tax­el, lipo­so­mal dox­oru­bicin (plus car­bo­platin in tripleneg­a­tive breast can­cer) for neoad­ju­vant treat­ment of high-risk ear­ly breast can­cer (GeparOc­to-GBG 84): A ran­domised phase III tri­al. Eur J Can­cer 106:181–192, 2019.

Loibl S, Untch M, Bur­char­di N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlan­et­to J, Tesch H, Hanusch C, Engels K, Rezai M, Jack­isch C, Schmitt WD, von Minck­witz G, Thoma­l­la J, Küm­mel S, Raut­en­berg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A ran­domised phase II study inves­ti­gat­ing dur­val­um­ab in addi­tion to an anthra­cy­cline tax­ane-based neoad­ju­vant ther­a­py in ear­ly triple neg­a­tive breast can­cer — clin­i­cal results and bio­mark­er analy­sis of Gepar­Nue­vo study. Ann Oncol 30(8):1279–1288, 2019.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Mar­mé F, Cejal­vo JM, Mar­tinez-Gar­cia M, Gon­za­lez I, Lopez-Mar­tin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Mene­ses-Lorente G, Racek T, James I, Cep­pi M, Has­mann M, Weiss­er M, Cer­vantes A.Phase Ib study eval­u­at­ing safe­ty and clin­i­cal activ­i­ty of the anti-HER3 anti­body lum­re­tuzum­ab com­bined with the anti-HER2 anti­body per­tuzum­ab and pacli­tax­el in HER3-pos­i­tive, HER2-low metasta­t­ic breast can­cer. Invest New Drugs 36:848–859, 2018.

Fremd C, Jaeger D, Schneeweiss A. Tar­get­ed and immuno-biol­o­gy dri­ven treat­ment strate­gies for triple-neg­a­tive breast can­cer: cur­rent knowl­edge and future per­spec­tives. Expert Rev Anti­cancer Ther 23:1–14, 2018.

Schneeweiss A, Chia S, Hick­ish T, Har­vey V, Eniu A, Wal­dron-Lynch M, Eng-Wong J, Kirk S, Cortés J. Long-term effi­ca­cy analy­sis of the ran­domised, phase II TRYPHAENA car­diac safe­ty study: Eval­u­at­ing per­tuzum­ab and trastuzum­ab plus
stan­dard neoad­ju­vant anthra­cy­cline-con­tain­ing and anthra­cy­cline-free chemother­a­py reg­i­mens in patients with HER2-pos­i­tive ear­ly breast can­cer. Eur J Can­cer 89:27–35, 2018.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Bar­rios CH, Iwa­ta H, Diéras V, Hegg R, Im SA, Shaw Wright G, Hen­schel V, Molinero L, Chui SY, Funke R, Husain A, Win­er EP, Loi S, Emens LA; IMpassion130 Tri­al Inves­ti­ga­tors. Ate­zolizum­ab and Nab-Pacli­tax­el in Advanced Triple-Neg­a­tive Breast Can­cer. N Engl J Med 379:2108–2121, 2018

Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Beck­er S, Loef­fler LM, Kro­n­awit­ter U, Bolz G, Poten­berg J, Tauchert F, Al-Batran SE, Schneeweiss A. Mapisal Ver­sus Urea Cream as Pro­phy­lax­is for Capecitabine-Asso­ci­at­ed Hand-Foot Syn­drome: A Ran­dom­ized Phase III Tri­al of the AIO Qual­i­ty of Life Work­ing Group. J Clin Oncol 33:2444–9, 2015.